



Consulta de Atención Farmacéutica Patologías Viricas

Top Ten Artículos Mes Septiembre

- Bracchi. M and Pozniak. A. Observing the revolution: A commentary on the new GeSIDA HIVguidelines. Enferm Infecc Microbiol Clin. 2015;In press
- Acquah R, Graham H and Winter A. Quantifying polypharmacy in a large HIV-infected cohort. HIV Medicine (2015), 16, 583–584
- Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDSNational Plan recommended guidelines for initial antiretroviraltherapy in HIV-infected adults. Grupo de Experto GESIDA/ Plan Nacional del SIDA. Enferm Infecc Microbiol Clin. 2015;In press
- Velasco C et al. Prediction of higher cost of antiretroviral therapy (ART) according toclinical complexity. A validated clinical index. Enferm Infecc Microbiol Clin. 2015;In press
- Fabbiani M et al. Reduced risk of Efavirenz Discontinuation in Na  ive Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen. HIV Med.2015 [Epub ahead of print]
- Cao W et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization ofCD8+T-cellcounts. Clin Infect Dis.(2015). [Epub ahead of print]
- Manzardo C, Tuset M, Mir   JM and Gatell JM. Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos. Enferm Infecc Microbiol Clin. 2015;33(7):15–30
- Soriano V and Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015 Sep;10(5):309-15
- Lagging M et al. Grazoprevir plus peginterferon and ribavirin in treatmentnaive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat.2015. In Press
- Buti et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clin Infect Dis.2015 [Epub ahead of print]